{
  "id": 21197165,
  "title": "Street Calls of the Week",
  "url": "https://urgent.news/2026/11/22/street-calls-of-the-week",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-22T10:00:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/street-calls-of-the-week-93CH-5042451"
  },
  "original_language": "en",
  "account": "The week's stock market trends contradicted expectations. Analyst upgrades often led to declines, while downgrades accompanied relief. The biggest riser during this period was a micro-cap biotech firm based on promising trial data. Analyst rating changes were limited to one per trading day, chosen for the most significant close-to-close movement. Monday through Thursday's movements used final closing prices, while Friday's data, open during trading hours, represented a midday reading.\n\nMonday saw significant activity with downgrades and relief. Upgrades coincided with stock declines, and downgrades were followed by a sense of relief. Among the moves, micro-cap biotech stood out as the biggest winner due to positive trial data. One analyst raised Peabody Energy to Buy from Neutral, citing a post-earnings selloff pushing the company's value to around half its net asset value. This move resulted in Peabody Energy shares rising by 0.9%, although they later closed at a 2.8% decline.\n\nInvestors faced a mix of rating actions and operational hurdles. First Solar fell 5.2% due to mixed rating actions, but the timing of the analyst calls couldn't be linked to the trading session. Goldman Sachs upgraded United Natural Foods to Buy, with the stock closing at $51.99, up 7.4%. RBC downgraded CG Oncology, leading to a 6.9% drop in its share price.\n\nThe week's extremes in ratings occurred on Tuesday, with Monness, Crespi, Hardt downgrading Strategy to Sell, and Northland upgrading Camtek to Outperform. Northland's upgrade was driven by Nvidia's focus on advancing packaging capacity. William Blair upgraded Pyxis Oncology to Outperform from Market Perform, citing a significant US market opportunity for second-line head and neck cancer treatment. However, the biggest downgrade of the week was Williams Trading's decision to cut Dick's Sporting Goods to Sell, amid concerns over Nike's allocation cuts. The stock price fell by 5.9% after this downgrade.\n\nAnother notable downgrade was Monness' downgrade of Elastic to Neutral, resulting in a 2.8% decline in its stock price. Despite some stocks moving against the direction of the call, rating changes proved to be a valuable tool for confirming market trends. The week's most significant movements were fueled by data releases, deals, and overall market sentiment. The information presented in this article was generated with the assistance of AI and reviewed by a human editor.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}